Search for


TEXT SIZE

search for



CrossRef (0)
샇瑜대が寃궗 봽濡쒓렇옩 떊鍮숇룄議곗궗 寃곌낵蹂닿퀬(2017)
Annual Report on the External Quality Assessment Scheme for Hormones in Korea (2017)
J Lab Med Qual Assur 2018;40:77-84
Published online June 30, 2018
© 2018 Korean Association of External Quality Assessment Service.

諛뺥삎몢
Hyung-Doo Park

꽦洹좉븰援 쓽怨쇰븰 궪꽦꽌슱蹂묒썝 吏꾨떒寃궗쓽븰怨

Department of Laboratory Medicine and Genetics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
Correspondence to: Hyung-Doo Park Department of Laboratory Medicine and Genetics, Samsung Medical Center, Sungkyunkwan University School of Medicine, 81 Irwon-ro, Gangnam-gu, Seoul 06351, Korea Tel: +82-2-3410-0290 Fax: +82-2-3410-2719 E-mail: nayadoo@hanmail.net
援먯떊옄: 諛뺥삎몢 슦)06351 꽌슱떆 媛뺣궓援 씪썝濡 81, 꽦洹좉븰援 궪꽦꽌슱蹂묒썝 吏꾨떒寃궗쓽븰怨 Tel: 02)3410-0290, Fax: 02)3410-2719, E-mail: nayadoo@hanmail.net
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
 Abstract

2017뀈 븳엫긽寃궗젙룄愿由ы삊쉶 떊鍮숇룄議곗궗궗뾽뿉꽌 샇瑜대が寃궗봽濡쒓렇옩 샇瑜대が寃궗 I뿉꽌 11媛吏, 샇瑜대が寃궗 II뿉꽌 4媛吏쓽 寃궗빆紐⑹쑝濡 슫쁺릺뿀떎. 뿰 2쉶뿉 嫄몄퀜 쉶李⑤퀎濡 3媛쒖쓽 젙룄愿由щЪ吏덉씠 씠슜릺뿀쑝硫, 媛 湲곌뿉꽌 엯젰븳 寃궗빆紐⑹뿉 븳 젙蹂댁 寃곌낵瑜 湲곕컲쑝濡 寃궗湲곌린뿉 뵲씪 遺꾩꽍븯떎. 蹂닿퀬꽌뒗 쟾泥 李몄뿬湲곌쓽 듅꽦쓣 蹂댁뿬二쇰뒗 怨듯넻蹂닿퀬꽌 媛쒕퀎湲곌쓽 룊媛옄猷뚮 蹂댁뿬二쇰뒗 湲곌蹂 蹂닿퀬꽌濡 굹늻뼱 옉꽦븯떎. 젣떆맂 넻怨꾩뿉뒗 媛 洹몃9蹂 李몄뿬湲곌 닔, 룊洹, 몴以렪李, 蹂룞怨꾩닔, 以묒븰媛, 理쒖냼媛믨낵 理쒕媛믪씠 룷븿릺룄濡 븯怨, 湲곌蹂꾨낫怨좎꽌뒗 媛 寃궗빆紐⑸퀎濡 넻怨꾩튂瑜 蹂댁뿬二쇰뒗 몴, 엳뒪넗洹몃옩怨 젅鍮-젣떇뒪 李⑦듃濡 援ъ꽦릺룄濡 븯떎. 넻怨꾩튂瑜 젣떆븳 몴뿉뒗 媛 湲곌쓽 寃궗寃곌낵 遺꾨쪟蹂 넻怨꾩튂瑜 젣떆븯怨, 湲곗遺꾨쪟 꽭遺꾨쪟뿉꽌뒗 몴以렪李⑥닔瑜 븿猿 젣떆븯떎. 李몄뿬湲곌쓽 닔 寃궗옣鍮꾩쓽 遺꾪룷뿉 엳뼱꽌뒗 쟾泥댁쟻쑝濡 쟾뀈룄 겙 李⑥씠媛 뾾뿀吏留, 寃궗빆紐⑸퀎濡 李몄뿬湲곌쓽 닔媛 떎뼇븯떎. 쉶李⑤퀎濡 젙룄愿由щЪ吏덉쓽 냽룄媛 궙怨 李몄뿬湲곌쓽 닔媛 쟻쓣닔濡 蹂씠怨꾩닔뒗 긽쟻쑝濡 넂 寃쏀뼢쓣 蹂댁떎. 媛 湲곌뿉꽌 쇅遺젙룄愿由 寃곌낵瑜 빐꽍븯怨 샇瑜대が寃궗 옣鍮꾨 꽑깮븷 븣 씠 넻怨꾨텇꽍 옄猷뚭 쑀슜븷 寃껋쑝濡 깮媛곹븳떎.

In 2017, the Korean Association of External Quality Assessment Service developed a hormone proficiency testing program that comprised 11 test items for hormone I and four test items for hormone II. This program was conducted twice a year using three-level control materials. Data and results of each test item were analyzed by the respective institutions according to the test instruments. The report was prepared by dividing it into a common report that showed the characteristics of the overall participating institutions and an organization-specific report that showed the assessment data of individual institutions. The following statistical data were presented: the number of participating institutions per group, mean, standard deviation, coefficient of variation, median, minimum value, and maximum value. The individual report was composed of a table, histogram, and Levey-Jennings chart showing the statistics for each test item. The results of the assessment of each institution and the statistical data for each classification are presented in a table, and a standard deviation index was provided for both the company classification and classification by instruments. Although the total number of participating institutions and distribution of test instruments were not significantly different from the previous year, the number of participating institutions varied by test item. The coefficient of variation tended to be relatively high for each test item because the concentration of quality control materials was low and the number of participating institutions was small. I believe that these statistical analysis data are useful for analyzing external quality control results of the institutions and selecting an immunoassay test instrument for hormones.

Keywords : Korean Association of External Quality Assessment Service, Laboratory proficiency testing, Hormones
꽌 濡

븳엫긽寃궗젙룄愿由ы삊쉶뿉꽌뒗 2015뀈源뚯 슫쁺빐삤뜕 遺꾧낵 봽濡쒓렇옩쓽 슫쁺諛⑹떇쓣 2016뀈遺꽣 李⑥꽭 떊鍮숇룄議곗궗궗뾽 泥닿퀎濡 蹂寃쏀븯硫댁꽌 46媛 냼遺꾨쪟긽 봽濡쒓렇옩 떒쐞蹂 슫쁺泥닿퀎濡 쟾솚븯떎[1-3]. 엫긽솕븰 遺꾩빞뒗 以묐텇瑜섏긽쑝濡 냼蹂꺕蹂꺕泥댁븸꺕寃곗꽍寃궗, 씪諛섑솕븰寃궗, 삁븸媛뒪꺕쟾빐吏덀꺕씠삩寃궗, 궗臾쇱쭏寃궗, 떒諛깅㈃뿭寃궗, 깂닔솕臾쇈꺕吏吏덀꺕떒諛깆쭏꺕鍮꾪誘쇨궗, 샇瑜대が寃궗, 醫낆뼇몴吏옄寃궗, 빟臾쇨궗, 젙솗룄湲곕컲寃궗 벑 10媛吏쓽 봽濡쒓렇옩쑝濡 援ъ꽦릺뼱 엳怨, 以묐텇瑜 寃궗봽濡쒓렇옩뿉뒗 媛곴컖 14媛吏쓽 냼遺꾨쪟 봽濡쒓렇옩씠 룷븿릺뼱 엳떎[4]. 샇瑜대が寃궗봽濡쒓렇옩 2016뀈뿉 샇瑜대が寃궗 I濡 떆옉븯뿬 2017뀈뿉 샇瑜대が寃궗 II媛 異붽릺뿀떎. 샇瑜대が寃궗 I뿉꽌 떆뻾릺뒗 寃궗빆紐⑹ thyroid stimulating hormone (TSH)쓣 룷븿븳 11媛吏濡 꽑젙릺뿀떎. 샇瑜대が寃궗 II뿉뒗 vitamin D 벑 4媛吏 寃궗媛 異붽릺뿀떎. 씠뿉 2017뀈뿉 떎떆릺뿀뜕 샇瑜대が寃궗봽濡쒓렇옩뿉 븳 떊鍮숇룄議곗궗궗뾽 寃곌낵瑜 遺꾩꽍븯뿬 蹂닿퀬븯怨좎옄 븳떎.

옱猷 諛 諛⑸쾿

1. 긽

샇瑜대が寃궗봽濡쒓렇옩 뿰 2쉶뿉 嫄몄퀜 쉶李⑤퀎濡 3媛쒖쓽 젙룄愿由щЪ吏덉쓣 궗슜븯뿬 닔뻾릺뿀떎. 깋옣긽깭媛 쑀吏맆 닔 엳룄濡 븘씠뒪뙥씠 궡옣맂 듅닔 젣옉諛뺤뒪뿉 젙룄愿由щЪ吏덉쓣 꽔뼱꽌 李몄뿬 벑濡앷린愿쓣 긽쑝濡 샇瑜대が寃궗 I 봽濡쒓렇옩 臾쇱쭏 5썡 15씪(1李)怨 10썡 16씪(2李)뿉, 샇瑜대が寃궗 II 봽濡쒓렇옩 臾쇱쭏 3썡 6씪(1李)怨 8썡 29씪(2李)뿉 媛곴컖 諛쒖넚븯떎(Tables 1, 2).

Table 1 . Baseline data used in proficiency tests for hormone I in 2017.

꺿꺿긘ariableTrial

1st2nd
Delivery date2017. 5. 152017. 10. 16
Response date2017. 5. 155. 262017. 10. 1610. 27
Test
긖hyroid stimulating hormone505565
긃ree thyroxin (T4)501557
긖otal triiodothyronine (T3)453498
긖hyroglobulin7880
긖otal human chorionic gonadotropin141149
긖estosterone9295
긂stradiol (E2)114123
17-Hydroxyprogesterone43
긑rogesterone2933
긑rolactin95101
긖otal thyroxine (T4)9391

Table 2 . Baseline data used in proficiency tests for hormone II in 2017.

꺿꺿긘ariableTrial

1st2nd
Delivery date2017. 3. 62017. 8. 29
Response date2017. 3. 63. 172017. 8. 299. 8
Test
긆ntact parathyroid hormone112117
긂rythropoietin76
긖otal 25-hydroxy vitamin D131135
긑rocalcitonin142149

2. 젙룄愿由щЪ吏덇낵 寃궗빆紐

젙룄愿由щЪ吏덉 Bio-Rad궗쓽 Lyphochek Immunossay Control (Bio-Rad Laboratories, Hercules, CA, USA) 벑 궗엺 삁泥쓣 湲곗쭏濡 븳 븸긽 젣뭹쓣 궗슜븯떎. 샇瑜대が寃궗 I 봽濡쒓렇옩쓽 寃궗빆紐⑹ TSH, total thyroxine (TT4), free thyroxine (FT4), total triiodothyronine (TT3), thyroglobulin, total human chorionic gonadotropin (hCG), testosterone, estradiol (E2), 17-hydroxyprogesterone (17-OHP), progesterone, prolactin 벑 11媛吏떎. 샇瑜대が寃궗 II 봽濡쒓렇옩쓽 寃궗빆紐⑹ total 25-hydroxy vitamin D (Vit D), procalcitonin, parathyroid hormone (PTH), erythropoietin 벑 4媛吏떎. 젙룄愿由щЪ吏덉쓣 닔졊븳 李몄뿬湲곌뿉꽌뒗 寃궗 떆뻾 썑 吏젙맂 쉶떊 留덇컧씪 씠궡뿉 븳엫긽寃궗젙룄愿由ы삊쉶 떊鍮숇룄議곗궗궗뾽 솃럹씠吏(http://eqas.keqas.org)뿉 寃곌낵瑜 엯젰븯룄濡 븞궡븯떎.

3. 寃곌낵 뙋젙 諛 遺꾩꽍

媛 寃궗빆紐⑹뿉 빐 媛쒕퀎 湲곌뿉꽌 엯젰븳 寃궗湲곌린, 떆빟, 寃궗寃곌낵 벑뿉 뵲씪 넻怨꾨텇꽍쓣 떆뻾븯怨, 씠 넻怨꾧컪쓣 諛뷀깢쑝濡 쟾泥 李몄뿬湲곌쓽 듅꽦쓣 蹂댁뿬二쇰뒗 怨듯넻蹂닿퀬꽌 媛쒕퀎湲곌쓽 룊媛옄猷뚮 蹂댁뿬二쇰뒗 湲곌蹂 蹂닿퀬꽌濡 굹늻뼱 蹂닿퀬븯떎. 怨듯넻蹂닿퀬꽌뒗 쟾泥 李몄뿬湲곌, 룞씪 湲곌린쉶궗 궗슜湲곌, 룞씪 湲곌린 궗슜湲곌 벑 3떒怨꾨줈 洹몃9솕븯뿬 넻怨꾧컪쓣 젣떆븯떎(Fig. 1). 쟾泥 李몄뿬湲곌뿉 빐떦븯뒗 넻怨, 湲곌린쉶궗瑜 湲곗遺꾨쪟濡 븳 洹몃9쓽 넻怨, 듅젙 寃궗湲곌린濡 援щ텇븳 洹몃9쓽 넻怨꾨 泥섎━븯뿬 媛곴컖 젣떆븯떎. 젣떆맂 넻怨꾩뿉뒗 媛 洹몃9蹂 李몄뿬湲곌 닔, 룊洹, 몴以렪李, 蹂룞怨꾩닔, 以묒븰媛, 理쒖냼媛, 理쒕媛 벑씠 룷븿릺뼱 엳떎. 씠긽移섎 젣嫄고븯吏 븡 긽깭쓽 紐⑤뱺 李몄뿬湲곌쓽 젙蹂대 씠슜븯뿬 以묒븰媛, 理쒖냼媛, 理쒕媛 벑쓣 援ы뻽怨, 쟻젅븳 諛⑸쾿쑝濡 씠긽移섎 젣嫄고븳 썑쓽 옄猷뚮 諛뷀깢쑝濡 룊洹, 몴以렪李, 蹂룞怨꾩닔 벑쓣 怨꾩궛븯뿬 젣떆븯떎. 븳렪, 엫긽寃궗젙룄愿由ы삊쉶쓽 썝移숈뿉 뵲씪 룞씪 洹몃9뿉 냽븳 湲곌 닔媛 10媛 誘몃쭔씤 寃쎌슦뿉뒗 룊洹, 몴以렪李, 蹂룞怨꾩닔 벑쓣 젣떆븯吏 븡븯怨, 湲곌 닔媛 3媛 誘몃쭔씤 寃쎌슦뿉뒗 以묒븰媛믩룄 젣떆븯吏 븡븯떎. 씠긽移섎뒗 Tukey rule쓣 씠슜븯뿬 젣嫄고븯뒗뜲, 媛 빐떦 遺꾨쪟뿉꽌 75 percentile 媛(Q3)怨 25 percentile 媛(Q1)쓽 李(Q3닋Q1; interquartile range, IQR)쓽 1.5諛곕 珥덇낵븯뿬 Q1蹂대떎 궙嫄곕굹 Q3蹂대떎 넂 寃곌낵媛(竊쏲11.5횞IQR 삉뒗 竊얫3+1.5횞IQR)쑝濡 꽕젙븯떎.

Figure 1.

Summary report of the general statistics report for the hormone I proficiency testing program of the 2017 Korean External Quality Assessment Service.


湲곌蹂 蹂닿퀬꽌뒗 媛 寃궗빆紐⑸퀎濡 넻怨꾩튂瑜 蹂댁뿬二쇰뒗 몴, 엳뒪넗洹몃옩, 젅鍮-젣떇뒪 李⑦듃(Levey-Jennings chart)濡 援ъ꽦븯뿬 씪紐⑹슂뿰븯寃 蹂 닔 엳룄濡 븯떎(Fig. 2). 넻怨꾩튂瑜 젣떆븳 몴뿉뒗 媛 湲곌쓽 寃곌낵媛믨낵 媛 遺꾨쪟蹂 넻怨꾩튂瑜 젣떆븯怨, 몴以렪李⑥닔(standard deviation index, SDI)뒗 湲곗遺꾨쪟 꽭遺꾨쪟뿉꽌留 젣떆븯떎. 쟾泥 李몄뿬湲곌 옄猷뚯 媛 洹몃9蹂 李몄뿬湲곌쓽 닔媛 10媛 誘몃쭔씪 寃쎌슦뿉뒗 룊洹, 몴以렪李, 蹂씠怨꾩닔, SDI 벑쓣 젣떆븯吏 븡븯떎. 젅鍮-젣떇뒪 李⑦듃뒗 湲곗遺꾨쪟蹂 SDI瑜 씠슜븯뿬 옉꽦븯뒗뜲, 李몄뿬湲곌 닔 遺議깆쑝濡 SDI媛 젣떆릺吏 븡뒗 寃쎌슦뒗 젅鍮-젣떇뒪 李⑦듃뿉꽌룄 몴떆릺吏 븡룄濡 븯떎. 엳뒪넗洹몃옩뿉꽌뒗 쟾泥 李몄뿬湲곌쓽 遺꾪룷 湲곗遺꾨쪟蹂 遺꾪룷瑜 젣떆븯怨 媛 湲곌쓽 쐞移섎 몴떆븯떎. 엳뒪넗洹몃옩쓽 泥 踰덉㎏ 留덉留 留됰뒗 媛곴컖 쟾泥 李몄뿬湲곌쓽 寃곌낵遺꾪룷뿉꽌 2.5띁꽱씪 誘몃쭔怨 97.5띁꽱씪 씠긽뿉 빐떦븳떎.

Figure 2.

An example of an individual institutional report for the hormone II proficiency testing program of the 2017 Korean External Quality Assessment Service.


寃곌낵 諛 怨좎같

100媛 씠긽쓽 湲곌씠 李몄뿬븯뒗 寃궗빆紐⑹ 샇瑜대が寃궗 I 봽濡쒓렇옩뿉꽌 TSH, TT4, FT4, TT3, hCG, E2 벑 6媛吏쑝硫, 샇瑜대が寃궗 II 봽濡쒓렇옩뿉꽌 PTH, Vit D, procalcitonin 벑 3媛吏떎. 17-OHP erythropoietin 媛곴컖 4湲곌怨 7湲곌쑝濡 쟾泥 李몄뿬湲곌씠 10怨녹뿉 誘몄튂吏 븡븯떎. 遺遺꾩쓽 빆紐⑹뿉꽌뒗 쟾뀈룄 鍮꾩듂븯嫄곕굹 냼룺 利앷븳 李몄뿬湲곌 닔瑜 蹂댁떎. 媛묒긽꽑湲곕뒫寃궗 愿젴 빆紐⑸뱾쓽 떊鍮숇룄議곗궗궗뾽 李몄뿬湲곌 利앷 룺씠 겙 렪씠뿀뒗뜲, TSH寃궗쓽 寃쎌슦 2016뀈 떊鍮숇룄議곗궗뿉꽌 471湲곌, 2017뀈 1李⑥뿉꽌 505湲곌, 2017뀈 2李⑥뿉꽌 565湲곌씠 李몄뿬븯뿬 1뀈 룞븞 빟 20%쓽 李몄뿬湲곌 닔쓽 利앷瑜 蹂댁떎. 17-OHP怨 TT4瑜 젣쇅븳 遺遺꾩쓽 샇瑜대が寃궗 I 빆紐⑹뿉꽌 1李 떊鍮숇룄議곗궗蹂대떎 2李 議곗궗뿉꽌 李몄뿬湲곌쓽 닔媛 利앷븯떎.

샇瑜대が寃궗 I怨 샇瑜대が寃궗 II怨 빆紐⑸뱾뿉 븳 몢 李⑤쓽 떊鍮숇룄議곗궗뿉꽌 쟾泥 李몄뿬湲곌쓽 넻怨꾧컪쓣 媛곴컖 Table 3Table 4뿉 젙由ы븯떎. 샇瑜대が寃궗뒗 遺遺 쟾슜떆빟怨 湲곌린瑜 궗슜븯뒗뜲, 2李 떊鍮숇룄議곗궗뿉꽌 李몄뿬湲곌씠 565怨녹쑝濡 媛옣 留롮븯뜕 TSH寃궗쓽 寃쎌슦, 7媛 쉶궗뿉꽌 17醫낅쪟쓽 寃궗湲곌린媛 궗슜릺怨 엳뿀떎. 1李 떊鍮숇룄議곗궗 븣 TSH寃궗쓽 쟾泥 湲곌 젙諛룄뒗 蹂씠怨꾩닔(%)媛 CP-17-01, -02, -03 臾쇱쭏뿉꽌 媛곴컖 11.0%, 6.5%, 7.0%濡 10% 궡쇅瑜 蹂댁吏留, 理쒖냼媛믨낵 理쒕媛믪쓽 李⑥씠媛 臾댁쿃 겙 쁽긽씠 꽭 媛吏 젙룄愿由щЪ吏덉뿉꽌 怨듯넻쟻쑝濡 愿李곕릺뿀떎. TSH CP-17-03 臾쇱쭏쓽 寃쎌슦 505媛 쟾泥 李몄뿬湲곌쓽 蹂씠怨꾩닔(%)뒗 7.0%吏留, 理쒖냼媛믪씠 0.69 關IU/mL, 理쒕媛믪씠 42.21 關IU/mL濡 60諛 씠긽쓽 李⑥씠瑜 蹂댁떎. 씠뒗 떎젣濡 寃궗떎媛 寃곌낵媛 겙 李⑥씠瑜 蹂댁떎湲곕낫떎 寃궗寃곌낵 엯젰 떆 냼닔젏쓣 옒紐 李띿뿀嫄곕굹 寃곌낵蹂닿퀬 떒쐞瑜 李⑷컖븯뿬 諛쒖깮뻽쓣 寃껋쑝濡 異붿젙맂떎. TSH寃궗 媛숈씠 International System of Units (SI unit, mIU/L)怨 conventional unit (關IU/mL) 궗씠뿉 conversion factor媛 1씤 寃궗룄 엳吏留, FT4 寃궗寃곌낵瑜 SI unit (pmol/L)쑝濡 蹂닿퀬븯湲 쐞빐꽌뒗 conventional unit (ng/dL)뿉 conversion factor씤 12.9瑜 怨깊빐빞 븳떎. TT3쓽 寃쎌슦뿉뒗 conventional unit뿉꽌 SI unit쑝濡 蹂寃쏀븷 븣 conversion factor媛 0.0154濡 留ㅼ슦 옉쑝誘濡 conventional unit쓽 寃곌낵瑜 洹몃濡 엯젰븯硫 寃궗寃곌낵 李⑥씠媛 썾뵮 겕寃 踰뚯뼱吏 닔 엳떎. 뵲씪꽌 媛쒕퀎湲곌뿉꽌 떊鍮숇룄議곗궗 寃궗寃곌낵瑜 엯젰븷 븣 엫긽寃궗젙룄愿由ы삊쉶뿉꽌 슂援ы븯뒗 寃곌낵蹂닿퀬 떒쐞뿉 留욎텛뼱 엯젰븯吏 븡뒗 寃쎌슦뿉뒗 삤瑜섍 諛쒖깮븷 닔 엳떎.

Table 3 . Proficiency test results for hormone I in 2017.

꺿꺿긖estNo. of participantsQuality control no.Mean짹standard deviationCoefficient of variation (%)Median (min뱈ax)
1st
긖SH505CH-17-010.759짹0.08411.00.73 (0.321.40)
CH-17-024.992짹0.3256.54.96 (1.856.98)
CH-17-0325.805짹1.8137.025.90 (0.6942.21)
긃ree T4501CH-17-011.288짹0.20015.51.23 (0.7917.17)
CH-17-022.893짹0.36312.52.90 (2.1743.99)
CH-17-034.989짹0.84817.05.20 (1.4874.25)
긖otal T3453CH-17-011.093짹0.16915.41.07 (0.7314.43)
CH-17-021.840짹0.20311.01.89 (1.3126.65)
CH-17-032.911짹0.35512.23.01 (0.7736.45)
긖hyroglobulin78CH-17-013.46짹0.102.83.50 (2.530.2)
CH-17-022.41짹0.176.92.40 (1.9106.4)
CH-17-035.40짹0.173.15.40 (4.1172.0)
긖otal hCG141CH-17-013.08짹0.3210.53.10 (2.325.0)
CH-17-0219.14짹1.296.819.2 (16.150.0)
CH-17-03352.92짹16.534.7354.2 (312.7500.0)
긖estosterone92CH-17-011.0044짹0.05975.90.9995 (0.5009.750)
CH-17-025.1811짹0.667312.95.4500 (2.82040.944)
CH-17-0312.7386짹1.438611.313.195 (6.42095.457)
긂stradiol (E2)114CH-17-0141.52짹4.9111.842.95 (27.6103.0)
CH-17-02311.33짹66.3521.3280.25 (212.5500.6)
CH-17-03799.70짹210.4526.3701.30 (547.21,253.6)
17-OHP4CH-17-010.473짹0.0122.40.480 (0.460.56)
CH-17-022.358짹0.1867.92.340 (2.152.60)
CH-17-034.830짹0.4649.64.735 (4.385.47)
긑rogesterone29CH-17-010.946짹0.16117.00.91 (0.602.12)
CH-17-029.835짹1.19112.110.25 (7.0017.75)
CH-17-0322.592짹4.06418.024.21 (15.5038.26)
긑rolactin95CH-17-018.733짹1.75120.08.77 (0.5211.68)
CH-17-0219.821짹4.67323.619.91 (11.9326.94)
CH-17-0350.202짹11.51522.949.16 (33.1568.77)
긖otal T493CH-17-019.044짹0.7308.18.89 (7.1011.60)
CH-17-0212.203짹0.6865.612.24 (9.1015.40)
CH-17-0315.673짹1.66410.615.70 (11.2419.84)
2nd
긖SH565CH-17-040.780짹0.0628.00.79 (0.5730.01)
CH-17-055.667짹0.71512.65.54 (0.7333.92)
CH-17-0630.073짹4.23614.129.70 (0.8443.52)
긃ree T4557CH-17-040.992짹0.15015.11.01 (0.6215.19)
CH-17-052.507짹0.39315.72.51 (1.2844.47)
CH-17-064.273짹0.87120.44.30 (1.2268.12)
긖otal T3498CH-17-041.038짹0.14313.81.01 (0.6913.23)
CH-17-051.982짹0.1819.12.02 (1.2923.14)
CH-17-062.964짹0.34811.73.06 (1.7434.24)
긖hyroglobulin80CH-17-043.73짹0.133.43.70 (2.531.6)
CH-17-056.19짹0.203.26.20 (4.655.8)
CH-17-065.68짹0.193.35.70 (4.2117.0)
긖otal hCG149CH-17-042.36짹0.4117.22.30 (1.87.4)
CH-17-0519.03짹1.568.218.9 (14.750.0)
CH-17-06389.52짹21.475.5391.0 (337.8647.0)
긖estosterone95CH-17-040.9288짹0.06637.10.930 (0.2791.200)
CH-17-053.8974짹0.595615.34.132 (1.9304.720)
CH-17-069.2975짹1.230713.29.700 (4.39011.200)
긂stradiol (E2)123CH-17-0453.03짹6.0611.455.0 (34.0147.0)
CH-17-05279.90짹61.3921.9248.0 (205.0505.2)
CH-17-06635.18짹182.7028.8537.0 (440.01,016.8)
17-OHP3CH-17-040.613짹0.0406.60.62 (0.570.65)
CH-17-051.880짹0.0824.41.90 (1.791.95)
CH-17-063.630짹0.1042.93.68 (3.513.70)
긑rogesterone33CH-17-040.743짹0.11515.40.74 (0.541.75)
CH-17-059.488짹1.38914.69.71 (7.2717.95)
CH-17-0625.324짹6.09524.125.40 (17.2044.93)
긑rolactin101CH-17-048.726짹1.49517.18.841 (6.2711.88)
CH-17-0520.744짹3.90218.820.49 (13.5027.75)
CH-17-0651.301짹9.42818.450.73 (36.1869.71)
긖otal T491CH-17-047.617짹0.7509.87.59 (5.919.90)
CH-17-0510.664짹0.7256.810.64 (8.5513.10)
CH-17-0613.644짹1.42510.413.40 (10.3317.37)

Abbreviations: TSH, thyroid-stimulating hormone; T4, thyroxine; T3, triiodothyronine; hCG, human chorionic gonadotropin; 17-OHP, 17-hydroxyprogesterone.


Table 4 . Proficiency test results for hormone II in 2017.

꺿꺿긖estNo. of participantsQuality control no.Mean짹standard deviationCoefficient of variation (%)Median (min뱈ax)
1st
긑TH112CH-17-0130.1짹3.712.430 (2152)
CH-17-02486.7짹37.47.7483 (399827)
CH-17-031058.4짹73.36.91,055 (1051,780)
긂rythropoietin7CH-17-0113.47짹0.906.713.7 (0.8014.4)
CH-17-0258.76짹0.430.758.9 (19.064.5)
CH-17-03210.86짹8.764.2210.0 (104.8242.0)
긘itamin D131CH-17-019.08짹4.6951.79.3 (3.037.2)
CH-17-0217.17짹9.2854.015.1 (3.033.4)
CH-17-0357.40짹28.0648.939.9 (8.6105.7)
긑rocalcitonin142CH-17-010.588짹0.0213.60.59 (0.412.19)
CH-17-021.968짹0.31916.21.81 (0.428.86)
CH-17-0318.705짹3.07816.516.91 (0.4126.79)
2nd
긑TH117CH-17-0430.9짹3.09.631 (2054)
CH-17-05497.7짹26.35.3495 (4121,180)
CH-17-061091.2짹58.85.41,086 (9501,900)
긂rythropoietin6CH-17-0415.12짹1.6811.114.65 (13.518.1)
CH-17-0563.82짹4.226.663.40 (59.368.9)
CH-17-06220.53짹17.998.2220.6 (195.0246.0)
긘itamin D135CH-17-048.14짹4.6156.67.9 (018.9)
CH-17-0515.12짹8.7958.212.6 (3.032.4)
CH-17-0653.96짹28.7353.235.8 (28.2110.8)
긑rocalcitonin149CH-17-040.509짹0.0234.50.51 (0.281.20)
CH-17-051.790짹0.32518.11.59 (1.434.31)
CH-17-0620.028짹3.43917.218.17 (13.1662.91)

Abbreviations: PTH, intact parathyroid hormone; vitamin D, total 25-hydroxy vitamin D.


샇瑜대が寃궗 II쓽 4媛吏 寃궗빆紐⑸뱾 以 erythropoietin 꽭 媛吏 젙룄愿由щЪ吏덉뿉 븳 쟾泥 李몄뿬湲곌쓽 蹂씠怨꾩닔(%)媛 0.7%-6.7%濡 겕吏 븡 렪씠뿀뒗뜲, 李몄뿬湲곌쓽 닔媛 쟻 寃껋씠 쁺뼢쓣 誘몄낀쓣 닔 엳떎. 諛섎㈃, Vit D뒗 1李 떊鍮숇룄議곗궗뿉꽌 48.9%-54.0%쓽 蹂씠怨꾩닔 遺꾪룷瑜, 2李 議곗궗뿉꽌 53.2%-58.2%쓽 蹂씠怨꾩닔 遺꾪룷瑜 蹂댁뿬꽌 湲곌뱾쓽 寃궗寃곌낵媛 긽떦엳 룺꼻寃 遺꾪룷븯뒗 寃껋쓣 蹂 닔 엳뿀떎. 떎留 Vit D쓽 룞씪 湲곌린쉶궗蹂 넻怨꾩뿉꽌뒗 3.9%-13.8%쓽 蹂씠怨꾩닔 遺꾪룷瑜 蹂댁뿬꽌 媛숈 옣鍮꾨 궗슜븯뒗 湲곌뱾겮由щ뒗 鍮꾩듂븳 寃곌낵瑜 궛異쒗븯怨 엳뿀떎. 젙솗룄媛 넂 吏덈웾遺꾩꽍踰뺤쑝濡 Vit D瑜 痢≪젙븯뒗 湲곌 4怨녹쑝濡 쟾泥 131湲곌쓽 3% 닔以뿉 遺덇낵븯쑝硫, 遺遺꾩쓽 湲곌뿉꽌뒗 硫댁뿭痢≪젙踰뺤쓣 씠슜븯怨 엳뿀떎. 샇瑜대が寃궗뒗 븘吏곴퉴吏 몴以솕굹 씪移섑솕媛 씠猷⑥뼱吏吏 븡 寃쎌슦媛 留롮븘꽌 떎瑜 쉶궗 옣鍮꾨줈 痢≪젙븷 븣뿉뒗 李멸퀬移섏 痢≪젙媛뒫踰붿쐞 벑쓽 듅꽦쓣 怨좊젮븯뿬 빐꽍븷 븘슂媛 엳떎. PTH쓽 寃쎌슦 1李 議곗궗 떆 쟾泥 李몄뿬湲곌 112怨녹쓽 룊洹좎 30.1 pg/mL씠뿀뒗뜲, Siemens 옣鍮 궗슜湲곌(17怨)쓽 룊洹좎 26.8 pg/mL씠뿀뜕 諛섎㈃뿉 Abbott 옣鍮 궗슜湲곌(15怨)쓽 룊洹좎 45.0 pg/mL濡 Siemens 옣鍮 궗슜湲곌뱾蹂대떎 68% 뜑 넂 寃궗寃곌낵瑜 蹂댁떎. 媛꾪샊 룞씪쉶궗 洹몃9씠굹 룞씪湲곌린 궗슜 洹몃9쓽 닽옄媛 쟻뼱꽌 寃곌낵 쟻빀꽦 뿬遺瑜 뙋떒븯뒗 SDI 벑 넻怨꾩옄猷뚮 遺꾩꽍븷 닔 뾾뒗 寃쎌슦뿉뒗 媛 湲곌뿉꽌 쟾泥 李몄뿬湲곌 옄猷 벑쓣 李멸퀬븯뿬 寃곌낵媛 뿀슜踰붿쐞뿉 뱶뒗吏 뿬遺瑜 媛쒕퀎쟻쑝濡 뙋떒븯嫄곕굹, 寃궗떎 媛 鍮꾧탳瑜 닔뻾븯嫄곕굹, 룞猷 洹몃9씠 留롮 援젣쟻씤 떊鍮숇룄議곗궗瑜 닔뻾븯뒗 벑쓽 泥대갑踰뺤쓣 寃넗븯뒗 寃껋쓣 怨좊젮븷 븘슂媛 엳떎.

샇瑜대が寃궗 떊鍮숇룄議곗궗뒗 2016뀈遺꽣 떆뻾맂 샇瑜대が寃궗 I 봽濡쒓렇옩뿉 씠뼱 2017뀈遺꽣 샇瑜대が寃궗 II 봽濡쒓렇옩씠 異붽릺뼱 珥 15媛吏쓽 寃궗빆紐⑹쑝濡 슫쁺븯怨 엳쑝硫, 遺遺꾩쓽 빆紐⑹뿉꽌 李몄뿬湲곌씠 袁몄엳 利앷븯怨 엳떎.

References
  1. Jun SH, Song J, Song WH. Clinical Chemistry Subcommittee, Korean Association of External Quality Assessment Service. Annual report on the external quality assessment scheme for clinical chemistry in Korea (2015). J Lab Med Qual Assur 2016;38:111-9.
    CrossRef
  2. Jun SH, Song J. Clinical Chemistry Subcommittee, The Korean Association of External Quality Assessment Service. Annual report on the external quality assessment scheme for clinical chemistry in Korea (2014). J Lab Med Qual Assur 2015;37:115-23.
    CrossRef
  3. Jun SH, Song J. Clinical Chemistry Subcommittee; The Korean Association of Quality Assurance for Clinical Laboratory. Annual report on the external quality assessment scheme in clinical chemistry in Korea (2013). J Lab Med Qual Assur 2014;36:113-21.
    CrossRef
  4. Lee YW, Jeon BR, Kim JG, Jun SH, Yun YM, Chun S, et al. Annual report on the external quality assessment scheme for routine clinical chemistry in Korea (2016). J Lab Med Qual Assur 2017;39:61-75.
    CrossRef